A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

NCT00424775 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: MK0683, vorinostat

Sponsor

Merck Sharp & Dohme LLC